Jefferies analyst Roger Song downgrades CytomX Therapeutics (NASDAQ:CTMX) from Buy to Hold and lowers the price target from $12 to $2.
Brewing Competition Compels Paramount To Club Showtime Streaming Service With Paramount+
Paramount Global (NASDAQ:PARA) weighed aborting its Showtime streaming service and shifting its content into Paramount+, the Wall Street Journal reports.…